Paper II — 2025 March (Supplementary (SAY)) (2019 Scheme) — Qv
2 min read
Paper II
2025 March (Supplementary (SAY)) (2019 Scheme) · 100 marks · 180 min
Question
Drug of choice for treatment in this patient is
a) Cefuroxime
b) Ceftriaxone
c) Ceftazidime
d) Cefoxitin
Qv1.8 marksMCQs
Answer
- [x] b) Ceftriaxone
A third-generation cephalosporin (ceftriaxone or cefotaxime) forms the backbone of empirical/definitive antibiotic therapy for bacterial meningitis, including pneumococcal meningitis, with vancomycin added where resistant pneumococcal strains are a concern. Cefuroxime (a second-generation cephalosporin) has inferior CNS penetration and narrower coverage; ceftazidime and cefoxitin are not standard choices for pneumococcal meningitis (ceftazidime has relatively weaker Gram-positive/pneumococcal activity and is more commonly reserved for Pseudomonas coverage; cefoxitin is a cephamycin used mainly for anaerobic/mixed infections, not meningitis).